Chemical Tools for Probing Histone Deacetylase (HDAC) Activity

被引:0
|
作者
Masafumi Minoshima
Kazuya Kikuchi
机构
[1] Osaka University,Graduate School of Engineering
[2] Osaka University,Institute of Academic Initiatives
[3] Osaka University,Immunology Frontier Research Center (IFReC)
来源
Analytical Sciences | 2015年 / 31卷
关键词
Histone deacetylase; fluorogenic probes; activity-based probes; positron emission tomography;
D O I
暂无
中图分类号
学科分类号
摘要
Histone deacetylases (HDACs) enzymes are responsible for removing epigenetic markers on histone proteins, which results in chromatin inactivation and gene repression. An evaluation of HDAC activity is essential for not only determining the physiological function of HDACs, but also for developing HDAC-targeting drugs. This review focuses on the chemical tools used to detect HDAC activity. We highlight activity-based probes and positron emission tomography probes based on the chemical structure of the inhibitors. We also summarize fluorogenic probes used in single-step methods for HDAC detection. These fluorogenic probes are designed based on the nucleophilicity of the amino group, aggregation via electrostatic interactions, and changes in the DNA binding properties. These fluorogenic systems may enable facile and rapid screening to evaluate HDAC inhibitors, which will contribute to the development of epigenetic drugs.
引用
收藏
页码:287 / 292
页数:5
相关论文
共 50 条
  • [31] Histone deacetylase inhibitors abrogate the levels and activity of estrogen receptor (ER) α and histone deacetylase (HDAC) 6 in human breast cancer cells (BCCs)
    Fiskus, W.
    Mohapatra, A.
    Bali, P.
    Balasis, M.
    Rao, R.
    Atadja, P.
    Wu, J.
    Bhalla, K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 177 - 177
  • [32] THE ROLE OF HISTONE DEACETYLASE (HDAC) IN VPA EFFICACY AND TERATOGENICITY
    Loescher, W.
    EPILEPSIA, 2010, 51 : 176 - 176
  • [33] Cloning and characterization of a histone deacetylase, HDAC9
    Zhou, XB
    Marks, PA
    Rifkind, RA
    Richon, VM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10572 - 10577
  • [34] Discovering Histone Deacetylase Substrates Using the HDAC Toolbox
    Leng, Katherine
    Fierke, Carol
    Wolfson, Noah
    Castaneda, Carol Ann
    Sullivan, Eric
    Lopez, Jeffrey
    PROTEIN SCIENCE, 2017, 26 : 209 - 209
  • [35] Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
    Shah, Rashmi R.
    DRUG SAFETY, 2019, 42 (02) : 235 - 245
  • [36] A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging
    Fleming, Cassandra L.
    Ashton, Trent D.
    Nowell, Cameron
    Devlin, Mark
    Natoli, Anthony
    Schreuders, Jeannette
    Pfeffer, Frederick M.
    CHEMICAL COMMUNICATIONS, 2015, 51 (37) : 7827 - 7830
  • [37] The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
    Vaca, Hugo R.
    Celentano, Ana M.
    Agustina Toscanini, Maria
    Heimburg, Tino
    Ghazy, Ehab
    Zeyen, Patrik
    Hauser, Alexander-Thomas
    Oliveira, Guilherme
    Elissondo, Maria C.
    Jung, Manfred
    Sippl, Wolfgang
    Camicia, Federico
    Cecilia Rosenzvit, Mara
    PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (03):
  • [38] Potential Role of Histone Deacetylase (HDAC) in Multiple Sclerosis
    Zhang, Fanglin
    Sriram, Subramaniam
    ANNALS OF NEUROLOGY, 2010, 68 (04) : S57 - S57
  • [39] The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia.
    West, Derek A.
    Lucas, David M.
    Davis, Melanie E.
    De lay, Michael D.
    Johnson, Amy J.
    Guster, Sara E.
    Freitas, Michael A.
    Parthun, Mark R.
    Wang, Dasheng
    Kulp, Samuel K.
    Grever, Michael R.
    Chen, Ching-Shih
    Byrd, John C.
    BLOOD, 2006, 108 (11) : 794A - 795A
  • [40] CRA-024781:: A potent histone deacetylase (HDAC) inhibitor with antitumor activity in vitro and in vivo
    Buggy, JJ
    Cao, ZA
    Bass, KE
    Balasubramanian, S
    Schultz, BE
    Liu, LA
    Leung, L
    Davis, JR
    Ngadimo, D
    Misialek, S
    Verner, E
    Dalrymple, SA
    Young, PR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9081S - 9081S